Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies

Chronic activation of the Bruton’s tyrosine kinase (BTK)-mediated B-cell receptor (BCR) signaling is a hallmark of many B-cell lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). Ibrutinib, an FDA approved, orally administered BTK inhibitor,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapoor, Isha, Li, Yue, Sharma, Arishya, Zhu, Huayuan, Bodo, Juraj, Xu, Wei, Hsi, Eric D., Hill, Brian T., Almasan, Alexandru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892912/
https://www.ncbi.nlm.nih.gov/pubmed/31801949
http://dx.doi.org/10.1038/s41419-019-2158-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892912/
https://www.ncbi.nlm.nih.gov/pubmed/31801949
http://dx.doi.org/10.1038/s41419-019-2158-0

Ejemplares similares